PTH and neoplasm: Compared with other osteoforming and antiresorptive drugs that can have negative effects on tumor pathology, such as estrogen management or human recombinant parathyroid hormone agents, it can be a first option for preventing and treating bone demineralization and its consequences when they are not severe [73,74,75].